Nalini Morris, DO
Psychiatry · Canton, OHNPI 1700904083
Payments from drug & device makers
Across 434 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- AbbVie$931
- Johnson & Johnson$904
- Alkermes, Inc.$837
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$820
- Teva Pharmaceuticals USA, Inc.$742
- plus $3K from 21 others
Across 6 payments — averaging $210.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
What the payments were for
- Food & beverage$7,85498%
- Education$1462%
- Gifts$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 38 | $1,255 |
| AbbVie(2 entities) | 90 | $931 |
| Johnson & Johnson | 35 | $904 |
| Alkermes, Inc. | 43 | $837 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 38 | $820 |
| Teva Pharmaceuticals USA, Inc. | 52 | $742 |
| Otsuka America Pharmaceutical, Inc. | 27 | $546 |
| Vanda Pharmaceuticals Inc. | 17 | $307 |
| E.r. Squibb & Sons, L.L.C. | 19 | $281 |
| Lundbeck LLC | 14 | $243 |
| Ironshore Pharmaceuticals Inc. | 8 | $165 |
| Sunovion Pharmaceuticals Inc. | 5 | $148 |
| Corium, LLC | 11 | $123 |
| Noven Therapeutics, LLC | 7 | $117 |
| Supernus Pharmaceuticals, Inc. | 1 | $113 |
| Axsome Therapeutics, Inc. | 5 | $105 |
| Indivior Inc. | 6 | $80 |
| Eisai Inc. | 2 | $55 |
| Collegium Pharmaceutical, Inc. | 3 | $53 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Jazz Pharmaceuticals Inc. | 1 | $28 |
| Tempus AI, Inc | 1 | $27 |
| Avanir Pharmaceuticals, Inc. | 2 | $26 |
| Neuronetics, Inc. | 2 | $25 |
| Vertical Pharmaceuticals, LLC | 2 | $24 |
| Almatica Pharma LLC | 1 | $16 |
| Validus Pharmaceuticals LLC | 2 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$476
- INVEGA SUSTENNA$130
- INVEGA TRINZA$130
- INVEGA$130
- SPRAVATO$130
- LATUDA$124
- ARISTADA INITIO$119
- INGREZZA$113
- QELBREE$113
- ABILIFY MAINTENA$104
- ABILIFY ASIMTUFII$104
How this compares
$8,000 in reported general payments places this provider in the 85th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 70 | $563,890 |
| Austedo XrDeutetrabenazine | 47 | $325,215 |
| AustedoDeutetrabenazine | 47 | $314,569 |
| VraylarCariprazine Hcl | 187 | $240,284 |
| Invega SustennaPaliperidone Palmitate | 56 | $182,939 |
| AristadaAripiprazole Lauroxil | 53 | $152,152 |
| CaplytaLumateperone Tosylate | 74 | $114,622 |
| Abilify MaintenaAripiprazole | 27 | $79,186 |
| LatudaLurasidone Hcl | 44 | $68,217 |
| Abilify AsimtufiiAripiprazole | 12 | $67,770 |
| RexultiBrexpiprazole | 40 | $61,613 |
| SpravatoEsketamine Hcl | 50 | $56,075 |
| NuedextaDextromethorphan Hbr/Quinidine | 31 | $50,917 |
| LybalviOlanzapine/Samidorphan Malate | 33 | $49,838 |
| Paliperidone ErPaliperidone | 194 | $43,596 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $742 | $639,78494 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,255 | $563,89070 claims |
| AbbVieVraylar, Fetzima | $931 | $247,055202 claims |
| Johnson & JohnsonInvega Sustenna, Spravato | $904 | $239,014106 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Abilify Asimtufii, Rexulti | $546 | $208,56879 claims |
| Alkermes, Inc.Aristada, Lybalvi | $837 | $201,99086 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $820 | $114,62274 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $148 | $68,21744 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $26 | $50,91731 claims |
| Axsome Therapeutics, Inc.Auvelity | $105 | $37,33960 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Canton
- Shishuka MalhotraCanton$15M
- Pradeep ManudhaneCanton$1.5M
- Henry NasrallahCincinnati$3.8M
- Otto DuenoDayton$3.1M
- Diab AlmhanaAvon Lake$2.7M
- Mohamed Abdel AzizWest Chester$2.6M
- Fred RomeoColumbus$2.3M
- Mark WoyshvilleMiddleburg Heights$2.2M
- Amita PatelDayton$2.1M
- Caleb AdlerCincinnati$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.